Connect with us

Hi, what are you looking for?

Friday, Apr 19, 2024
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

Business

Tilray Medical launches new ‘CannaPoints” program

The company also released 7 new products under its Tilray and Aphria brands

Tilray reports $1.1B in losses during its third quarter of 2023, acquires Hexo for US$56M
Image via Tilray

Tilray Brands, Inc.  (Nasdaq: TLRY; TSX: TLRY) has partnered with a mobile app developer and started a points-based program to earn rewards.

On Thursday, the leading cannabis producer announced the CannaPoints program in partnership with Strainprint Technologies, which is a mobile app focused on medical cannabis tracking. The goal of the program is to earn rewards, offer patients new products, teach them about cultivars and their effects as well as curate optimal personal consumption schedules.

Strainprint is a cannabis data and analytics firm that was founded in Toronto in 2016.

Founded in Toronto Canada in 2016, StrainprintTM Technologies is the leader in demand-side cannabis data and analytics

The company also announced the addition of new products under its Tilray and Aphria portfolios including Tilray’s Sinaloa Gold, Sapphire Scout, Chem Cookies, Powdered Donuts #8 and Aphria’s Sherbet Cookies, Banana Punch and Monkey Butter.

Read more: Tilray receives approval for CBD oral solution in Australia and New Zealand

Read more: Poland approves Tilray Medical products for distribution and wholesale

“We’re proud to expand our medical cannabis portfolio in Canada and broaden our offerings for our growing patient community,” Tilray president Blair McNeil.

“Our new CannaPoints program serves to guide our patients on their medical cannabis journey and provide additional support as needed.”

In Canada, the company offers brands such as Tilray, Aphria, Broken Coast, and Symbios. It recently received approval from the Natural Health Science Foundation (NHSF) for its Purified OS CBD100 oral solution which will be utilized in clinical trials conducted in New Zealand and Australia.

Tilray stock went up by 7.38 per cent on Friday to $5.24 on the Toronto Securities Exchange.

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Cannabis

The deal is projected to generate craft beer pro forma revenue of $250 million

Cannabis

Tilray's net revenue increased by 20 per cent to $184 million, compared to $153 million in the prior year quarter

Cannabis

The company will be supporting the cancer and patient care conference ONCOWELLNESS

Cannabis

It also reported $145.6 million in net revenue compared to $144.1 million in the prior quarter